Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Hepatitis C

Free Subscription Articles published in Hepatology Retrieve available abstracts of 35 articles: HTML format

Single Articles

June 2025
1. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
   Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
   Hepatology. 2025;81:E181.
   PubMed    
   
   
   February 2025
2. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
   Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
   Hepatology. 2025;81:609-624.
   PubMed     Abstract available
   
   
   January 2025
3. PATEL K, Asrani SK, Fiel MI, Levine D, et al
   Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
   Hepatology. 2025;81:358-379.
   PubMed     Abstract available
   
   
   November 2024
4. 
   Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.
   Hepatology. 2024;80:E86.
   PubMed    
   
   
   October 2024
5. COLPITTS CC, Baumert TF
   Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions.
   Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132.
   PubMed    
   
   
   
6. OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al
   Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion.
   Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114.
   PubMed     Abstract available
   
   
   August 2024
7. VAN DER MEER AJ, Sonneveld MJ
   Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
   Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
   PubMed    
   
   
   
8. STAFYLIS C, Vij AP, Klausner JD
   Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and treatment to achieve elimination in the united states.
   Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051.
   PubMed    
   
   
   July 2024
9. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
   Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
   Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005.
   PubMed     Abstract available
   
   
   
10. 
    Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    PubMed    
    
    
    June 2024
11. LAW JL, Drummer HE
    Bridging the gap: A new tool to down select HCV vaccine candidates.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
    PubMed    
    
    
    
12. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    PubMed    
    
    
    
13. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    PubMed    
    
    
    
14. CORNBERG M, Wedemeyer H
    Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
    Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
    PubMed    
    
    
    May 2024
15. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    PubMed     Abstract available
    
    
    
16. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    PubMed    
    
    
    
17. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    PubMed     Abstract available
    
    
    
18. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    PubMed    
    
    
    April 2024
19. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    PubMed     Abstract available
    
    
    March 2024
20. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    PubMed     Abstract available
    
    
    
21. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    PubMed     Abstract available
    
    
    
22. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    PubMed    
    
    
    February 2024
23. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed     Abstract available
    
    
    
24. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    PubMed    
    
    
    
25. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    PubMed    
    
    
    January 2024
26. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    PubMed     Abstract available
    
    
    
27. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    PubMed     Abstract available
    
    
    November 2023
28. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    PubMed     Abstract available
    
    
    July 2023
29. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    PubMed     Abstract available
    
    
    June 2023
30. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    PubMed     Abstract available
    
    
    
31. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    PubMed    
    
    
    May 2023
32. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    PubMed    
    
    
    April 2023
33. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    PubMed    
    
    
    
34. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available
    
    
    
35. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.